BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical

Reuters

Yesterday

BRIEF-Silexion <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical

Dec 2 (Reuters) - Silexion Therapeutics Corp SLXN.O:

SILEXION THERAPEUTICS RECEIVES POSITIVE FEEDBACK FROM GERMAN HEALTH AUTHORITY ON DESIGN OF PHASE 2/3 CLINICAL TRIAL IN PANCREATIC CANCER
SILEXION THERAPEUTICS CORP - ON TRACK TO INITIATE PHASE 2/3 TRIAL IN H1 2026
SILEXION THERAPEUTICS CORP - REGULATORY SUBMISSIONS IN ISRAEL BY Q4 2025, GERMANY BY Q1 2026

Source text: ID:nGNX1n8HTR

Further company coverage: SLXN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2588056944"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588056944\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588056944?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588056944","market":"nz","top_or_hot":-1,"title":"BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Silexion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical </title></head><body><p><span>Dec 2 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SLXN\">Silexion Therapeutics Corp</a> <span>SLXN.O</span>:</p><ul><li><p>SILEXION THERAPEUTICS RECEIVES POSITIVE <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> FROM GERMAN HEALTH AUTHORITY ON DESIGN OF PHASE 2/3 CLINICAL TRIAL IN PANCREATIC CANCER</p></li><li><p>SILEXION THERAPEUTICS CORP - ON TRACK TO INITIATE PHASE 2/3 TRIAL IN H1 2026</p></li><li><p>SILEXION THERAPEUTICS CORP - REGULATORY SUBMISSIONS IN ISRAEL BY Q4 2025, GERMANY BY Q1 2026</p></li></ul><p>Source text: <span>ID:nGNX1n8HTR</span></p><p>Further company coverage: <span>SLXN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-02 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Silexion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical </title></head><body><p><span>Dec 2 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SLXN\">Silexion Therapeutics Corp</a> <span>SLXN.O</span>:</p><ul><li><p>SILEXION THERAPEUTICS RECEIVES POSITIVE <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> FROM GERMAN HEALTH AUTHORITY ON DESIGN OF PHASE 2/3 CLINICAL TRIAL IN PANCREATIC CANCER</p></li><li><p>SILEXION THERAPEUTICS CORP - ON TRACK TO INITIATE PHASE 2/3 TRIAL IN H1 2026</p></li><li><p>SILEXION THERAPEUTICS CORP - REGULATORY SUBMISSIONS IN ISRAEL BY Q4 2025, GERMANY BY Q1 2026</p></li></ul><p>Source text: <span>ID:nGNX1n8HTR</span></p><p>Further company coverage: <span>SLXN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLXN","symbol_name":"Silexion Therapeutics Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA4MJNPK:1","article_id":"2588056944","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588056944","pubTimestamp":1764683748,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical Dec 2 (Reuters) - Silexion Therapeutics Corp SLXN.O:SILEXION THERAPEUTICS RECEIVES P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLXN":"Silexion Therapeutics Corp","BK4139":"生物科技"},"translate_title":"简介-Silexion Therapeutics获得德国卫生当局对2/3期临床设计的积极反馈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLXN":0.9},"content_text":"BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical Dec 2 (Reuters) - Silexion Therapeutics Corp SLXN.O:SILEXION THERAPEUTICS RECEIVES POSITIVE FEEDBACK FROM GERMAN HEALTH AUTHORITY ON DESIGN OF PHASE 2/3 CLINICAL TRIAL IN PANCREATIC CANCERSILEXION THERAPEUTICS CORP - ON TRACK TO INITIATE PHASE 2/3 TRIAL IN H1 2026SILEXION THERAPEUTICS CORP - REGULATORY SUBMISSIONS IN ISRAEL BY Q4 2025, GERMANY BY Q1 2026Source text: ID:nGNX1n8HTRFurther company coverage: SLXN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}